Dr. Tun is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4500 San Pablo Rd S
Jacksonville, FL 32224Phone+1 904-953-2000
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1998 - 2001
MedStar Health/Harbor HospitalResidency, Internal Medicine, 1995 - 1998
University Institute of Medicine 1Class of 1990
Certifications & Licensure
FL State Medical License 1998 - 2026
MD State Medical License 1997 - 1999- American Board of Internal Medicine Hematology
Clinical Trials
- Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2008 Feb 01
- Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
- Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma Start of enrollment: 2019 Jan 30
- Join now to see all
Publications & Presentations
PubMed
- 142 citationsPathway Signature and Cellular Differentiation in Clear Cell Renal Cell CarcinomaHan W. Tun, Laura A. Marlow, Christina A. von Roemeling, Simon J. Cooper, Pamela A. Kreinest
Plos One. 2010-05-18 - 32 citationsDoes bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?Omran Saifi, William G Breen, Scott C Lester, William G Rule, Bradley Stish
Radiotherapy and Oncology. 2022-01-01 - 78 citationsThe mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E. Witzig, Craig B. Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson
Blood. 2015-07-16
Journal Articles
- Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal LymphomaLisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood
Abstracts/Posters
- Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic ExperienceHan W. Tun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...Han W. Tun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...Han W. Tun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Treasure Trove of Genes Key to Kidney Cancer Revealed by ResearchJuly 1st, 2014
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
